Cite
HARVARD Citation
Dandona, P. et al. (2017). Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet. 5 (11), pp. 864-876. [Online].